Clinical Trials on Respiratory Syncytial Virus Infections in United States

Total 11946 results

Evidation Health
Biomedical Advanced Research and Development Authority

Recruiting

Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections (WAVE)

COVID-19 | Influenza, Human | Influenza A | Respiratory Syncytial Virus (RSV) | Influenza B

United States
University of Oxford

Active, not recruiting

RESCEU: Defining the Burden of RSV Disease

Respiratory Syncytial Virus Infections | RSV Infection

United Kingdom
Imperial College London
Medical Research Council; Wellcome Trust; National Institute for Health Research...

Terminated

A Study of Protective Immunity Against RSV and Influenza in Experimental Human Challenge of Volunteers

Influenza, Human | Respiratory Syncytial Virus Infections

United Kingdom
Enanta Pharmaceuticals, Inc

Recruiting

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. (RSVHR)

RSV Infection

United States, Poland, Spain, Taiwan, Bulgaria, Argentina, Puerto Rico, Czechia, Brazil, Israel, Malaysia, Netherlands, Slovakia, South Africa
Merck Sharp & Dohme LLC

Active, not recruiting

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

RSV Infection

United States, Australia, Canada, Chile, Colombia, Czechia, Finland, France, Germany, Greece, Hong Kong, Hungary, Italy, Japan, Malaysia, Mexico, New Zealand, Norway, Peru, Puerto Rico, Singapore, South Africa, Spain, Taiwan, Thailand, Tu... and more
Novavax

Completed

RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly

Respiratory Syncytial Virus (RSV)

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age (LID)

Respiratory Syncytial Virus Infections

United States
ModernaTX, Inc.

Recruiting

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Respiratory Syncytial Virus | Human Metapneumovirus

United Kingdom, Spain, United States, Australia, Canada, Poland, South Africa, Panama
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
Gilead Sciences

Completed

Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

Respiratory Syncytial Virus

Korea, Republic of, Taiwan, Israel, United States, France, Singapore, Sweden, Australia, Canada, United Kingdom, Brazil, Germany, Netherlands, Spain, Switzerland
MedImmune LLC

Terminated

A Study to Evaluate the Efficacy of MEDI7510 in Older Adults

Respiratory Syncytial Virus

United States, Chile, South Africa, Canada, Estonia, Lithuania, Latvia
Arrow Therapeutics

Completed

A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT

Respiratory Syncytial Virus Infections

United Kingdom
Merck Sharp & Dohme LLC

Completed

Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)

Respiratory Syncytial Virus

United Kingdom
Pfizer

Completed

Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)

Respiratory Syncytial Virus (RSV)

United Kingdom
MedImmune LLC

Completed

Study to Evaluate MEDI-534 in Healthy Adults

Respiratory Syncytial Virus Infections | Parainfluenza Infections

United States
Meissa Vaccines, Inc.

Recruiting

Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

Respiratory Syncytial Virus (RSV)

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
MicroDose Therapeutx, Inc

Completed

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers

Respiratory Syncytial Virus Infections | Drug Safety

United States
Blue Lake Biotechnology Inc.

Completed

Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults

Respiratory Syncytial Virus Infections

United States
Novavax

Completed

RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.

Respiratory Syncytial Virus Infections

United States
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

Respiratory Syncytial Virus

United States, Panama
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

Respiratory Syncytial Virus (RSV)

United States
ModernaTX, Inc.

Active, not recruiting

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

Respiratory Syncytial Virus

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
ModernaTX, Inc.

Recruiting

A Study to Investigate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults

Respiratory Syncytial Virus

Canada, United States, United Kingdom, Puerto Rico
ModernaTX, Inc.

Recruiting

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

Respiratory Syncytial Virus

Canada, United Kingdom, Japan, United States, Chile, Denmark, Panama, South Africa
Blue Lake Biotechnology Inc.

Recruiting

A Study of BLB-201 RSV Vaccine in Infants and Children

Respiratory Syncytial Virus Infections

United States
Indiana University School of Medicine
Thrasher Research Fund

Completed

Assessment of Airway Obstruction in Infants With Lower Respiratory Infections

Respiratory Syncytial Virus Infections | Bronchiolitis

United States
Merck Sharp & Dohme LLC

Completed

Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005)

Respiratory Syncytial Viruses

United Kingdom
Pfizer

Recruiting

A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV

Respiratory Syncytial Virus Infections

United States, Israel, Japan, Korea, Republic of, South Africa, Argentina, Canada
GlaxoSmithKline

Completed

A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women

Respiratory Syncytial Virus Infections

United States, Germany, Finland
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
GlaxoSmithKline

Withdrawn

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

Respiratory Syncytial Virus Infections

Finland, United States, Spain
Codagenix, Inc

Recruiting

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children

Respiratory Syncytial Virus Infections

United States, South Africa
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus

Respiratory Syncytial Viruses

United States, Belgium, Canada, Hungary, Japan, Poland
Bavarian Nordic

Completed

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

Respiratory Syncytial Virus Infections

United States
Novavax

Completed

RSV F Dose-Ranging Study in Women

Respiratory Syncytial Virus Infections

United States
Pfizer

Completed

A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants

Respiratory Syncytial Virus Infections

United Kingdom
Hvivo
Pfizer

Completed

Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults

Respiratory Syncytial Virus Infections

United Kingdom
University of Oxford

Completed

RSV Observational Study 2

Respiratory Syncytial Virus Infections

United Kingdom
Alios Biopharma Inc.

Completed

A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176

Respiratory Syncytial Virus Infections

United Kingdom
Gilead Sciences

Completed

Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV) (Challenge)

Respiratory Syncytial Virus Infections

United Kingdom
Pfizer

Completed

Pharmacokinetics and Safety of RV521 Formulations (C19007)

Respiratory Syncytial Virus Infections

United Kingdom
MedImmune LLC

Completed

Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age (CP149)

Respiratory Syncytial Virus Infections | Respiratory Viral Infections | Parainfluenza Virus 3, Human

United States
GlaxoSmithKline

Completed

Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study

Respiratory Syncytial Virus Infections

United States, Belgium
GlaxoSmithKline

Completed

Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women

Respiratory Syncytial Virus Infections

United States, Australia, Germany, Czechia
Respivert Ltd

Completed

RV568 - Viral Challenge With RSV

Respiratory Syncytial Virus Infections

United Kingdom
Janssen Sciences Ireland UC

Terminated

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection

Virus Diseases | Respiratory Syncytial Virus Infections

Australia, Spain, Belgium, Sweden, Netherlands, Brazil, Germany, Argentina, Philippines, United States
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and Toddlers

Respiratory Syncytial Virus Infections

United States, Finland, Ghana, Honduras, India, Spain, Thailand

3

Subscribe